Using the Collaborative Cross for Model Studies of Intestinal Cancer

Information

  • Research Project
  • 9771600
  • ApplicationId
    9771600
  • Core Project Number
    R21CA202496
  • Full Project Number
    7R21CA202496-03
  • Serial Number
    202496
  • FOA Number
    PAR-15-340
  • Sub Project Id
  • Project Start Date
    7/1/2016 - 9 years ago
  • Project End Date
    6/30/2019 - 6 years ago
  • Program Officer Name
    SHARMAN, ANU
  • Budget Start Date
    9/18/2018 - 7 years ago
  • Budget End Date
    6/30/2019 - 6 years ago
  • Fiscal Year
    2017
  • Support Year
    03
  • Suffix
  • Award Notice Date
    9/18/2018 - 7 years ago
Organizations

Using the Collaborative Cross for Model Studies of Intestinal Cancer

? DESCRIPTION (provided by applicant: Gastrointestinal (GI) cancers are worldwide health issues that are both highly prevalent and deadly. The ability to understand the genetic factors influencing the change of normal stomach, small intestine and colorectal tissues towards the initiation, growth and progression to cancer is essential to the goals of precision medicine. As with every cancer, being able to identify people at risk before the cancer appears provides the greatest opportunity to intervene and prevent the development of life-threatening disease. To better model human disease, the Collaborative Cross (CC) was generated and has captured the tremendous genomic variation present within one mammalian species, the mouse. The CC are recombinant inbred (RI) lines created from the genomic contributions of 8 inbred founder strains, chosen because of their evolutionary diversity with each other. The unique combination of alleles within the different CC lines facilitates 1) the identification of phenotypes more extree than have been observed in common inbred laboratory strains, and 2) the opportunity for high resolution mapping of loci influencing complex traits. Our studies represent an avenue to investigate GI tumor phenotypes governed by allelic variation. We propose to use a sensitized background, namely a mutation in the adenomatous polyposis coli (Apc) gene coupled with a resistant Mom2R allele, and mate these mice with the CC lines in a one-step cross to screen for dominant modifiers that lead to increased tumorigenesis or altered tumor profiles. We have incorporated a mutant Apc allele because the APC gene is one of the top 5 genes mutated in all 3 GI cancers in humans. The use of the CC lines coupled with the use of our unique, long-lived, but sensitized congenic strain background provides an innovative approach to the study of GI cancers.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R21
  • Administering IC
    CA
  • Application Type
    7
  • Direct Cost Amount
    13161
  • Indirect Cost Amount
    7370
  • Total Cost
    20531
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    393
  • Ed Inst. Type
    SCH ALLIED HEALTH PROFESSIONS
  • Funding ICs
    NCI:20531\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SETON HALL UNIVERSITY
  • Organization Department
    OTHER HEALTH PROFESSIONS
  • Organization DUNS
    079324315
  • Organization City
    SOUTH ORANGE
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    070792646
  • Organization District
    UNITED STATES